2026-10-25
MiniMed Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,465 −1.17%
S&P 7,723 −0.27%
GOLD $4,035 −0.40%
BTC $81,733 +0.57%
VIX 16.46 −2.66%
latest tape · as of 16:04 UTC
The Screen · Healthcare · Medical Instruments & Supplies
MiniMed Group, Inc.
MMED · Nasdaq · USD · Market cap $5.0B
MiniMed Group, Inc.
Not yet scored18.34 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price18.34 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.22)
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 18.34 against the desk's fair-value range, base estimate 20.06, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.22, read 2026-10-28
- Ethical screen not yet scored
Price18.34 USD
Fair value20.06
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Distribution17.80+3.0% to today Markdown gives way to Distribution after a 16% slide in 4 weeks
2026-10-02Read Markdown21.12-13.2% to today ✓Accumulation gives way to Markdown after an 8% rise in 5 weeks
2026-08-25Read Accumulation19.60-6.4% to today Markup gives way to Accumulation after a 16% rise in 3 weeks
2026-08-05Read Markup16.93+8.3% to today ✓Distribution gives way to Markup after a 12% rise in 5 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
MiniMed Group, Inc. holds its Distribution at $18.34. Consolidating, no directional conviction, held for 2 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $18.34 |
| Valuation | N/A trailing · 25.64 forward price to earnings |
| Values screen | Not scored · score 70.0 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 3.13% | Below 33% | Interest-bearing debt is just 3.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 10.76% | Below 49% | Money owed to the company is 10.8% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
MiniMed Group, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
MiniMed Group, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 9.4% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +44% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsDiabetes kit maker priced above its worth
Picture a patient relying on an insulin pump to stay steady through the day. The hardware matters, yet MiniMed runs at an 11% loss and negative return on equity while growing revenue 16%. At 25.6 times forward earnings on a business still losing money, the shares sit 4% above our fair value with no margin of safety left.
We pass. Analyst targets sit higher, yet the numbers show no durable edge and an unknown competitive moat. Ethical checks clear, but that alone does not turn losses into cash returns for owners.
Execution risk stays real in a crowded medtech field where reimbursement changes or new rivals can quickly widen the losses. The current price already bakes in optimism the balance sheet does not support.
Analysis, not advice.
| Forward P/E | 25.6xpriced for continued growth |
| EPS, trailing | -1.53 |
| EPS, forward | 0.69 |
| Revenue growth | +16.6%steady growth |
| Profit margin | -9.7%currently unprofitable |
| Return on equity | -8.7%not currently earning a positive return on equity |
| Debt to equity | 1.63a meaningful debt load worth watching |
| Current ratio | 1.81healthy short-term liquidity |
| Short interest, float | 0.64% |
| 52-week range | 10.65 - 24.43 |
| Market cap | $5.0B |
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMMED trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Distribution · changed $17.80
-1.1% Entry 16
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. The street (12 analysts) rates it strong buy, with a mean price target of $22.
2026-10-21
Markdown $18.00
-8.7% Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading bearish. The street (12 analysts) rates it strong buy, with a mean price target of $22.
2026-10-14
Markdown $19.71
-6.7% Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22.
2026-10-02
Markdown · changed $21.12
+8.4% Entry 13
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 8.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22.
2026-09-01
Accumulation $19.49
+0.0% Entry 12
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31
Accumulation $19.49
+0.0% Entry 11
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30
Accumulation $19.49
+0.0% Entry 10
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-29
Accumulation $19.49
+0.0% Entry 9
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-28
Accumulation $19.49
+0.0% Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-27
Accumulation $19.49
-0.6% Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. The street (12 analysts) rates it strong buy, with a mean price target of $22. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- MiniMed Announces Board of Directors for its Next Chapter as an Independent Company Yahoo Finance · 13d ago
- Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up? Yahoo Finance · 14d ago
- Medtronic Completes Separation of MiniMed Group, Inc. Yahoo Finance · 14d ago
- MiniMed Completes Separation from Medtronic Yahoo Finance · 14d ago
- BC-Most Active Stocks Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
STVNStevanato Group S.p.A.
TFXTeleflex Incorporated
MMSIMerit Medical Systems, Inc.
BLCOBausch + Lomb Corporation
ICUIICU Medical, Inc.
NVSTEnvista Holdings Corporation
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $11.16 | +33.0% | · | $1,330 | +33.0% |
| 2 months | $13.92 | +6.6% | · | $1,066 | +6.6% |
| 3 months | $16.53 | -10.2% | · | $898 | -10.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MMED does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.